Obesity: Evolving Perceptions from Providers and Payers on Treatments for Chronic Weight Management

IPD’s recent Primary Market Insights report, “Obesity: Evolving Perceptions from Providers and Payers on Treatments for Chronic Weight Management,” analyzes the results from surveys completed by 30 primary care physicians and 30 endocrinologists to assess their prescribing preferences among anti-obesity medications (AOMs). These surveys capture early assessments of Eli Lilly’s Zepbound (tirzepatide) and Novo Nordisk’s Wegovy (semaglutide) for reduction in the risk of major adverse cardiovascular events (MACE) as well as anticipated usage of oral semaglutide.

The report features insights regarding providers’ awareness of treatments for chronic weight management, current and anticipated prescribing patterns for AOMs, prior treatment history of patients receiving Zepbound, payer management of AOMs, and more. IPD Analytics’ Primary Market Insights provide a window into the dynamic market pulse of rapidly evolving disease areas, like obesity.